Results 121 to 130 of about 724,283 (165)

Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. [PDF]

BioDrugs, 2020
Lee SJ, Baek K, Lee S, Lee YJ, Park JE, Lee SG.   +5 more
europepmc   +1 more source

Correction to: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). [PDF]

J Crohns Colitis
europepmc   +1 more source

Core-CT Project news

Began with Sept.

core  

Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials. [PDF]

BioDrugs, 2020
Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ, Ystrøm CM, Lundin KEA, Kvien T, Jahnsen J.   +28 more
europepmc   +1 more source

Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry. [PDF]

BioDrugs, 2020
Kim HA, Lee E, Lee SK, Park YB, Shin K.
europepmc   +1 more source

Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis. [PDF]

J Drug Assess, 2019
Gheorghe C, Svoboda P, Mateescu B.
europepmc   +1 more source

Likheter mellan CT-P13 och infliximab : En litteraturstudie

, 2020
openaire   +1 more source

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Gastroenterology, 2021
BACKGROUND AIMS: This study compared pharmacokinetics, symptomatic and endoscopic efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab biosimilar CT-P13 (CT-P13 SC) vs intravenous CT-P13 (CT-P13 IV) in patients with ...
Byong Duk Ye, Walter Reinisch, Shomron Ben-Horin   +2 more
exaly   +2 more sources

Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness

Advances in Therapy, 2021
Introduction: Long-term, real-world safety and effectiveness data are required to support biosimilar use. This analysis pooled 5-year findings from observational studies of infliximab biosimilar CT-P13 treatment in patients with rheumatoid arthritis (RA),
Sang Joon Lee, Jae Hee Cheon, Yun Jeong Lim   +2 more
exaly   +2 more sources